Breakthrough Award Levels 1 and 2 – HT942524BCRPBTA122
- Funding Level 1 – up to USD$450,000 over 3 years or
- Funding Level 1 – Partnering PI Option – up to USD$750,000 over 3 years or
- Funding Level 2 – up to USD$1M over 3 years or
- Funding Level 2 – Population Science and Prevention Studies – up to USD$1.5M over 4 years or
- Funding Level 2 – Partnering PI Option – up to USD $1.5M over 3 or
- Funding Level 2 – Population Science and Prevention Studies Partnering PI Option – up to USD$2M over 4 years
- Letters of Intent due 12 September 2024
- supports promising research that has high potential to lead to or make breakthroughs in breast cancer
- population science and prevention studies investigate why certain human patient populations differ in cancer risk or clinical prognosis
- Document: Funding Opportunity – HT942524BCRPBTA122-GG
Clinical Research Extension Award II – HT942524BCRPCREA2
- up to USD$5M over 4 years or
- up to USD$6M over 4 years with Partnering PI option
- letters of intent due 12 September 2024
- supports research that extends or expands the data collection, follow-up and analysis of breast cancer clinical studies
- Document: Funding Opportunity: HT942524BCRPCREA2-GG
Era of Hope Scholar Award – HT942524BCRPEOHS2
- up to USD$3.5M over 4 years
- letters of intent due 23 July 2024
- supports independent, unmentored ECRs (<6 years) who have demonstrated significant potential to to effect meaningful change in breast cancer
- applicants should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research
- applicants should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention
- experience in breast cancer research not required
- research team must include at least 2 breast cancer advocates
- Document: Funding Opportunity – HT942524BCRPEOHS2-GG
